Emmessar Biotech And Nutrition (BOM:524768) Cyclically Adjusted Revenue per Share: ₹4.43 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524768 Emmessar Biotech And Nutrition Ltd BOM:524768
58 GF Score
Price ₹23.92
GF Value ₹18.76
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Emmessar Biotech And Nutrition Cyclically Adjusted Revenue per Share?

Emmessar Biotech And Nutrition BOM:524768 -1.52% 58 Cyclically Adjusted Revenue per Share is ₹4.43 as of Jun. 2026. GuruFocus rates BOM:524768 with a GF Score™ of 58/100 and a GF Value™ of ₹18.76 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Emmessar Biotech And Nutrition's adjusted revenue per share for the three months ended in Jun. 2026 was ₹0.117. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹4.43 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Emmessar Biotech And Nutrition's average Cyclically Adjusted Revenue Growth Rate was -6.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Emmessar Biotech And Nutrition was 0.60% per year. The lowest was -5.40% per year. And the median was -1.40% per year.

As of today (2026-08-23), Emmessar Biotech And Nutrition's current stock price is ₹23.92. Emmessar Biotech And Nutrition's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹4.43. Emmessar Biotech And Nutrition's Cyclically Adjusted PS Ratio of today is 5.40.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Emmessar Biotech And Nutrition was 9.98. The lowest was 2.88. And the median was 5.49.


Emmessar Biotech And Nutrition  (BOM:524768) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Emmessar Biotech And Nutrition's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=23.92/4.43
=5.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Emmessar Biotech And Nutrition was 9.98. The lowest was 2.88. And the median was 5.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Emmessar Biotech And Nutrition Cyclically Adjusted Revenue per Share Related Terms


Emmessar Biotech And Nutrition Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Emmessar Biotech And Nutrition's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmessar Biotech And Nutrition Cyclically Adjusted Revenue per Share Chart

Emmessar Biotech And Nutrition Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.23 5.52 5.43 5.01 4.67

Emmessar Biotech And Nutrition Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.75 4.78 4.78 4.67 4.43

BOM:524768 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emmessar Biotech And Nutrition's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmessar Biotech And Nutrition Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emmessar Biotech And Nutrition's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Emmessar Biotech And Nutrition's Cyclically Adjusted PS Ratio falls into.


BOM:524768
58GF Score
Emmessar Biotech And Nutrition Ltd BOM:524768
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emmessar Biotech And Nutrition Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emmessar Biotech And Nutrition's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.117/167.3573*167.3573
=0.117

Current CPI (Jun. 2026) = 167.3573.

Emmessar Biotech And Nutrition Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.128 105.961 0.202
201612 1.586 105.196 2.523
201703 1.406 105.196 2.237
201706 1.106 107.109 1.728
201709 1.071 109.021 1.644
201712 0.257 109.404 0.393
201803 0.082 109.786 0.125
201806 0.281 111.317 0.422
201809 0.107 115.142 0.156
201812 0.567 115.142 0.824
201903 0.303 118.202 0.429
201906 3.774 120.880 5.225
201909 0.113 123.175 0.154
201912 1.193 126.235 1.582
202003 1.722 124.705 2.311
202006 0.573 127.000 0.755
202009 2.153 130.118 2.769
202012 2.211 130.889 2.827
202103 9.034 131.771 11.474
202106 0.047 134.084 0.059
202109 0.072 135.847 0.089
202112 0.321 138.161 0.389
202203 0.295 138.822 0.356
202206 0.415 142.347 0.488
202209 0.135 144.661 0.156
202212 0.777 145.763 0.892
202303 0.623 146.865 0.710
202306 0.136 150.280 0.151
202309 0.167 151.492 0.184
202312 0.661 152.924 0.723
202403 0.152 153.035 0.166
202406 0.160 155.789 0.172
202409 0.683 157.882 0.724
202412 0.167 158.323 0.177
202503 0.223 157.552 0.237
202506 0.184 159.755 0.193
202509 0.185 162.289 0.191
202512 0.185 163.281 0.190
202603 0.186 164.272 0.189
202606 0.117 167.357 0.117

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹4.43 mean?
Emmessar Biotech And Nutrition (BOM:524768) has a Cyclically Adjusted Revenue per Share of ₹4.43 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Emmessar Biotech And Nutrition and its competitors.
Is Emmessar Biotech And Nutrition's Cyclically Adjusted Revenue per Share too high?
Emmessar Biotech And Nutrition's current Cyclically Adjusted Revenue per Share is ₹4.43. Overall, Emmessar Biotech And Nutrition has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emmessar Biotech And Nutrition's Cyclically Adjusted Revenue per Share compare to ZTS?
Emmessar Biotech And Nutrition's Cyclically Adjusted Revenue per Share of ₹4.43 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Emmessar Biotech And Nutrition and its competitors. Emmessar Biotech And Nutrition's current Cyclically Adjusted Revenue per Share is ₹4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmessar Biotech And Nutrition stock overvalued right now?
Based on GuruFocus' analysis, Emmessar Biotech And Nutrition (BOM:524768) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹18.76, compared to a current price of ₹23.92 — trading 27.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹4.43. Emmessar Biotech And Nutrition's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Emmessar Biotech And Nutrition (BOM:524768), the current Cyclically Adjusted Revenue per Share is ₹4.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emmessar Biotech And Nutrition (BOM:524768) Overvalued in 2026?

Based on GuruFocus' analysis, Emmessar Biotech And Nutrition stock appears to be overvalued. The current stock price of ₹23.92 is trading 27.5% above its estimated GF Value™ of ₹18.76. GuruFocus considers Emmessar Biotech And Nutrition to be Modestly Overvalued.

Key valuation signals for BOM:524768:

  • Cyclically Adjusted Revenue per Share: ₹4.43
  • GF Value™: ₹18.76 vs. price of ₹23.92 (27.5% above fair value)
  • GF Score™: 58/100 with 1 warning sign

No single metric tells the full story. See the BOM:524768 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emmessar Biotech And Nutrition Business Description

Address 38, Cawasji Patel Street, 29, Kamer Building, 4th floor, Fort, Mumbai, MH, IND, 400001
Emmessar Biotech And Nutrition Ltd is a healthcare company. The company is engaged in the manufacturing and marketing of fine chemicals products, and healthcare and nutritional products. The company caters to patients with obstinate skin problems, muscle problems, bone problems, and other debilitating chronic physical ailments. The business segments of the company are Healthcare, Fine Chemicals, and Rent on Immovable property of which the majority of the revenue is derived from the Rent on Lease land segment.
58GF Score

Get the complete analysis for BOM:524768

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹23.92
Price
₹18.76
GF Value